Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | GRK6 | P43250 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981242 | 0.85 | KAT2B (0.64) | KAT2BTSHRCYP3A4GRK6MAPT | |
| SCHEMBL14981759 | 0.84 | KAT2B (0.97) | KAT2BTSHRCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL513348 | 0.83 | KAT2B (1.00) | KAT2BTSHRCYP3A4MAPT | |
| SCHEMBL978709 | 0.82 | TSHR (0.62) | KAT2BTSHRCYP3A4GRK6MAPT | |
| SCHEMBL3636228 | 0.82 | KAT2B (0.69) | KAT2BTSHRCYP3A4GRK6MAPT | |
| SCHEMBL9081742 | 0.81 | TSHR (0.60) | KAT2BTSHRCYP3A4GRK6MAPT | |
| SCHEMBL17263168 | 0.81 | KAT2B (0.59) | KAT2BTSHRCYP3A4GRK6MAPT | |
| SCHEMBL15082923 | 0.81 | MAPT (0.61) | KAT2BTSHRCYP3A4GRK6MAPT | |
| SCHEMBL24185371 | 0.78 | KAT2B (0.64) | KAT2BTSHRCYP3A4MAPTHTR6 | |
| SCHEMBL22725388 | 0.78 | KAT2B (0.57) | KAT2BTSHRCYP3A4GRK6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0837854-B1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-0830348-B1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6110911-A | ADMINISTERING NEUROPROTECTANT/ANTICONVULSANT TO PATIENT | WARNER-LAMBERT COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| US-5874426-A | USEFUL IN THE TREATMENT OF STROKE, CEREBRAL ISCHEMIA, OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, STATUS EPILEPTICUS, ANOXIA, SEIZURE DISORDER | WARNER-LAMBERT COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0837854-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0830348-A1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-03-25 | — | — | EP | disclosed |
| US-5654303-A | FOR TREATING NERVOUS SYSTEM OR CARDIOVASCULAR SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996040650-A1 | CYCLIC AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040651-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |